Debra Richardson

8PUBLICATIONS
54CO-AUTHORS
Predictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Mar 13, 2025
Myeloid targeting antibodies PY159 and PY314 for platinum-resistant ovarian cancer.

Oladapo O Yeku, Minal Barve, Winston W Tan

|Jan 12, 2025
First-in-human phase I trial of the bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, SL-172154 in patients with platinum-resistant ovarian cancer.

Nehal J Lakhani, Daphne Stewart, Debra L Richardson

|Jul 30, 2024
Effectiveness of PARP Inhibitor Maintenance Therapy in Ovarian Cancer by BRCA1/2 and a Scar-Based HRD Signature in Real-World Practice.

Debra L Richardson, Julia C F Quintanilha, Natalie Danziger

|Apr 16, 2024
ENGOT-EN20/GOG-3083/XPORT-EC-042 - A phase III, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma: rationale, methods, and trial design.

Ignace Vergote, Alejandro Perez Fidalgo, Giorgio Valabrega

|Oct 05, 2023
Phase IIa Study of PLX2853 in Gynecologic Cancers With Known ARID1A Mutation and Phase Ib/IIa Study of PLX2853/Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer.

Linda R Duska, Dmitriy Zamarin, Erica Hamilton

|Sep 05, 2023
Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer.

Ignace Vergote, Jose Alejandro Pérez-Fidalgo, Erika Paige Hamilton

Pageof 2

Frequent Collaborators

3 joint publications

Bradley J Monk

2 joint publications

Oladapo O Yeku

2 joint publications

Mansoor Raza Mirza

2 joint publications

Ignace Vergote